A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7345-7355

  Christensen, James G ^a,b   Schreck, Randall ^a   Burrows, Jon ^a   Kuruganti, Poonam ^a   Chan, Emily ^a   Le, Phuong ^a   Chen, Jeffrey ^a   Wang, Xueyan ^a   Ruslim, Lany ^a   Blake, Robert ^a   Lipson, Kenneth E ^a   Ramphal, John ^a   Do, Steven ^a   Cui, Jingrong J ^a   Cherrington, Julie M ^a   Mendel, Dirk B ^a  

^a SUGEN INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(2,6 DICHLOROBENZYL)SULFONYL] 3 [[3,5 DIMETHYL 4 [[2 (PYRROLIDIN 1 YLMETHYL)PYRROLIDIN 1 YL]CARBONYL] 1H PYRROL 2 YL]METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; C MET RECEPTOR TYROSINE KINASE; FOCAL ADHESION KINASE; LIGAND; PHA 665752; PHOSPHOLIPASE C; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CATALYSIS; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; KIDNEY; KINETICS; LUNG NEOPLASMS; MICE; MICE, NUDE; NIH 3T3 CELLS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RATS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 10744228765     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Laird, A. D., and Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs, 21: 51-64, 2003.
2. Naldini, L., Vigna, E., Narsimhan, R. P., Gaudino, G., Zarnegar, R., Michalopoulos, G. K., and Comoglio, P. M. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene, 6: 501-504, 1991.
3. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F., and Aaronson, S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (Wash. DC), 251: 802-804, 1991.
4. Naldini, L., Weidner, K. M., Vigna, E., Gaudino, G., Bardelli, A., Ponzetto, C., Narsimhan, R. P., Hartmann, G., Zamegar, R., and Michalopoulos, G. K. Scatter factor and hepatocyte growth factor are indistinguishable ligands for MET receptor. EMBO J., 10: 2867-2878, 1991.
5. Rodrigues, G. A., and Park, M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene, 9: 2019-2027, 1994.
6. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 77: 261-271, 1994.
7. Fournier, T. M., Lamorte, L., Maroun, C. R., Lupher, M., Band, H., Langdon, W., and Park, M. Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion. Mol. Biol. Cell, 11: 3397-3410, 2000.
8. Furge, K. A., Zhang, Y. W., and Vande Woude, G. F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 19: 5582-5589, 2000.
9. Di Renzo, M. F., Narsimhan, R. P., Olivero, M., Bretti, S., Giordano, S., Medico, E., Gaglia, P., Zara, P., and Comoglio, P. M. Expression of the Met/ HGF receptor in normal and neoplastic human tissues. Oncogene, 6: 1997-2003, 1991.
10. Sonnenberg, E., Weidner, K. M., and Birchmeier, C. Expression of the met-receptor and its ligand, HGF-SF during mouse embryogenesis. Exs, 65: 381-394, 1993.
11. Comoglio, P. M., and Boccaccio, C. Scatter factors and invasive growth. Semin. Cancer Biol., 11: 153-165, 2001.
12. Jiang, W., Hiscox, S., Matsumoto, K., and Nakamura, T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol.-Hematol., 29: 209-248, 1999.
13. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (Lond.), 376: 768-771, 1995.
14. Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., and Birchmeier, C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature (Lond.), 373: 699-702, 1995.
15. Tsarfaty, I., Rong, S., Resau, J. H., Rulong, S., da Silva, P. P., and Vande Woude, G. F. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science (Wash. DC), 263: 98-101, 1994.
16. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer. S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bemues, M., Richard. S., Lips, C. J., Walther, M. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., and Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.
17. Lee, J. H., Han, S. U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., and Vande Woude, G. F. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene, 19: 4947-4953, 2000.
18. Park, W. S., Dong, S. M., Kim, S. Y., Na, E. Y., Shin, M. S., Pi, J. H., Kim, B. J., Bae, J. H., Hong, Y. K., Lee, K. S., Lee, S. H., Yoo, N. J., Jang, J. J., Pack, S., Zhuang, Z., Schmidt, L., Zbar, B., and Lee, J. Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res., 59: 307-310, 1999.
19. Di Renzo, M. F., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., and Giordano, S. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res., 1: 147-154, 1995.
20. Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., Stefani, A. D., Valente, G., Giordano, S., Cortesina, G., and Comoglio, P. M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19: 1547-1555, 2000.
21. Bellusci, S., Moens, G., Gaudino, G., Comoglio, P., Nakamura, T., Thiery, J. P., and Jouanneau, J. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene, 9: 1091-1099, 1994.
22. Jeffers, M., Rong, S., Anver, M., and Vande Woude, G. F. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene, 13: 853-856, 1996.
23. Rong, S., Segal, S., Anver, M., Resau, J. H., and Vande Woude, G. F. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Nat. Acad. Sci. USA, 91: 4731-4735, 1994.
24. Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., and Vande Woude, G. F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Nat. Acad. Sci. USA, 94: 11445-11450, 1997.
25. Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S., and Vande Woude, G. F. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol., 12: 5152-5158, 1992.
26. Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka. T., Kriebel, P., Anver, M., Aaronson, S. A., and Merlino, G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Nat. Acad. Sci. USA, 94: 701-706, 1997.
27. Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D., and Wang, T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J. Clin. Investig., 97: 2872-2877, 1996.
28. Parr, C., Hiscox, S., Nakamura, T., Matsumoto, K., and Jiang, W. G. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int. J. Cancer, 85: 563-570, 2000.
29. Michieli, P., Basilico, C., Pennacchietti, S., Maffe, A., Tamagnone, L., Giordano, S., Bardelli, A., and Comoglio, P. M. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene, 18: 5221-5231, 1999.
30. Atabey, N., Gao, Y., Yao, Z. J., Breckenridge, D., Soon, L., Soriano, J. V., Burke, T. R., Jr., and Bottaro, D. P. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J. Biol. Chem., 276: 14308-14314, 2001.
31. Abounader, R., Ranganathan, S., Lal, B., Fielding, K., Book, A., Dietz, H., Burger, P., and Laterra, J. Reversion of human glioblastoma malignancy by UI small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst., 91: 1548-1556, 1999.
32. Morotti, A., Mila, S., Accomero, P., Tagliabue, E., and Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene, 21: 4885-4893, 2002.
33. Rong, S., Oskarsson, M., Faletto, D., Tsarfaty, I., Resau, J. H., Nakamura, T., Rosen, E., Hopkins, R. F., 3rd, and Vande Woude, G. F. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ., 4: 563-569, 1993.
34. Blake, R. A., Broome, M. A., Liu, X., Wu, J., Gishizky, M., Sun, L., and Courtneidge, S. A. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell Biol., 20: 9019-9027, 2000.
35. Christensen, J. G., Schreck, R. E., Chan, E., Wang, X., Yang, C., Liu, L., Cui, J., Sun, L., Wei, J., Cherrington, J. M., and Mendel, D. B. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin. Cancer Res., 7: 4230-4238, 2001.
36. Stoker, M., Gherardi, E., Perryman, M., and Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (Lond.), 327: 239-242, 1987.
37. Weidner, K. M., Sachs, M., and Birchmeier, W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell Biol., 121: 145-154, 1993.
38. Nakaigawa, N., Weirich, G., Schmidt, L., and Zbar, B. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. Oncogene, 19: 2996-3002, 2000.
39. Liu, Z. X., Yu, C. F., Nickel, C., Thomas, S., and Cantley, L. G. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J. Biol. Chem., 277: 10452-10458, 2002.
40. Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., and Salgia, R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev., 13: 41-59, 2002.
41. Boccaccio, C., Ando, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., and Comoglio, P. M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (Lond.), 391: 285-288, 1998.
42. Sachs, M., Weidner, K. M., Brinkmann, V., Walther, I., Obermeier, A., Ullrich, A., and Birchmeier, W. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J. Cell Biol., 133: 1095-1107, 1996.
43. Weidner, K. M., Di Cesare, S., Sachs, M., Brinkmann, V., Behrens, J., and Birchmeier, W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature (Lond.), 384: 173-176, 1996.
44. Khwaja, A., Lehmann, K., Marte, B. M., and Downward, J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem., 273: 18793-18801, 1998.
45. Tanimura, S., Nomura, K., Ozaki, K., Tsujimoto, M., Kondo, T., and Kohno, M. Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J. Biol. Chem., 277: 28256-28264, 2002.
46. Karihaloo, A., O'Rourke, D. A., Nickel, C., Spokes, K., and Cantley, L. G. Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis. J. Biol. Chem., 276: 9166-9173, 2001.
47. Potempa, S., and Ridley, A. J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell, 9: 2185-2200, 1998.
48. Royal, I., Fournier, T. M., and Park, M. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis. J. Cell. Physiol., 173: 196-201, 1997.
49. Xiao, G. H., Jeffers, M., Bellacosa, A., Mitsuuchi, Y., Vande Woude, G. F., and Testa, J. R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Nat. Acad. Sci. USA, 98: 247-252, 2001.
50. Day, R. M., Cioce, V., Breckenridge, D., Castagnino, P., and Bottaro, D. P. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene, 18: 3399-3406, 1999.
51. Gual, P., Giordano, S., Williams, T. A., Rocchi, S., Van Obberghen, E., and Comoglio, P. M. Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene, 19: 1509-1518, 2000.